ABN Amro Investment Solutions Decreases Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• ABN Amro Investment Solutions reduced its Thermo Fisher Scientific stake by 13.9% in the fourth quarter, selling 20,391 shares and leaving it with 126,699 shares worth about $73.4 million.
• Thermo Fisher reported better-than-expected quarterly results, with EPS of $5.44 versus estimates of $5.25 and revenue of $11.01 billion versus $10.86 billion expected. Revenue rose 6.2% year over year.
• The company raised its dividend to $0.47 per quarter from $0.43, while analysts still see the stock favorably overall with a Moderate Buy consensus and an average price target of $616.10.

ABN Amro Investment Solutions cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 13.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 126,699 shares of the medical research company's stock after selling 20,391 shares during the quarter. Thermo Fisher Scientific makes up 1.1% of ABN Amro Investment Solutions' investment portfolio, making the stock its 19th largest holding. ABN Amro Investment Solutions' holdings in Thermo Fisher Scientific were worth $73,416,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in TMO. Howard Capital Management Inc. increased its holdings in Thermo Fisher Scientific by 0.5% in the 4th quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company's stock worth $1,791,000 after acquiring an additional 16 shares during the last quarter. Petros Family Wealth LLC grew its holdings in Thermo Fisher Scientific by 3.9% during the 4th quarter. Petros Family Wealth LLC now owns 456 shares of the medical research company's stock valued at $264,000 after buying an additional 17 shares in the last quarter. Salomon & Ludwin LLC grew its holdings in Thermo Fisher Scientific by 1.6% during the 4th quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company's stock valued at $669,000 after buying an additional 17 shares in the last quarter. Pallas Capital Advisors LLC grew its holdings in Thermo Fisher Scientific by 1.5% during the 4th quarter. Pallas Capital Advisors LLC now owns 1,256 shares of the medical research company's stock valued at $728,000 after buying an additional 18 shares in the last quarter. Finally, Red Door Wealth Management LLC grew its holdings in Thermo Fisher Scientific by 0.8% during the 4th quarter. Red Door Wealth Management LLC now owns 2,156 shares of the medical research company's stock valued at $1,250,000 after buying an additional 18 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $451.74 on Thursday. The company has a market cap of $167.88 billion, a PE ratio of 24.83, a price-to-earnings-growth ratio of 1.98 and a beta of 0.88. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The stock has a 50-day moving average price of $482.22 and a 200-day moving average price of $539.63. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company's revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the company posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Friday, March 13th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.43. Thermo Fisher Scientific's dividend payout ratio is presently 10.34%.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of recent analyst reports. Citigroup lifted their target price on Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a "buy" rating in a report on Friday, January 30th. Robert W. Baird reduced their target price on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a report on Friday, April 24th. TD Cowen reduced their target price on Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating for the company in a report on Friday, January 30th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Finally, Barclays dropped their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating for the company in a research report on Tuesday, April 14th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $616.10.

Insider Buying and Selling

In related news, COO Gianluca Pettiti sold 400 shares of the business's stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. The trade was a 1.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.